

Benjamin Kasenda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7233912/publications.pdf>

Version: 2024-02-01

89
papers

3,190
citations

147726

31
h-index

168321

53
g-index

91
all docs

91
docs citations

91
times ranked

4946
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated meta-research analysis. <i>PLoS Medicine</i> , 2022, 19, e1003980.	3.9	21
2	Characteristics and survival of patients with cancer with intended off-label use—a cohort study. <i>BMJ Open</i> , 2022, 12, e060453.	0.8	2
3	Reporting quality of clinical trial protocols: a repeated cross-sectional study about the Adherence to SPIrit Recommendations in Switzerland, Canada and Germany (ASPIRE-SCAGE). <i>BMJ Open</i> , 2022, 12, e053417.	0.8	3
4	Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. <i>JAMA Network Open</i> , 2021, 4, e210380.	2.8	8
5	Reporting quality of trial protocols improved for non-regulated interventions but not regulated interventions: A repeated cross-sectional study. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 340-349.	2.4	7
6	Evaluation of Planned Subgroup Analysis in Protocols of Randomized Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e2131503.	2.8	2
7	Reliability of Trial Information Across Registries for Trials With Multiple Registrations. <i>JAMA Network Open</i> , 2021, 4, e2128898.	2.8	12
8	High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. <i>Blood Advances</i> , 2020, 4, 3378-3381.	2.5	34
9	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1300-1307.	1.2	9
10	Characteristics and interpretation of subgroup analyses based on tumour characteristics in randomised trials testing target-specific anticancer drugs: design of a systematic survey. <i>BMJ Open</i> , 2020, 10, e034565.	0.8	0
11	Prediction of RECRUITment In randomized clinical Trials (RECRUIT-IT)—rationale and design for an international collaborative study. <i>Trials</i> , 2020, 21, 731.	0.7	10
12	Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. <i>JAMA Network Open</i> , 2020, 3, e2024406.	2.8	53
13	Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system—an international study of feasibility and efficacy in routine clinical practice. <i>British Journal of Haematology</i> , 2020, 189, 879-887.	1.2	41
14	Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects. <i>Trials</i> , 2020, 21, 896.	0.7	9
15	Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. <i>British Journal of Haematology</i> , 2019, 184, 957-968.	1.2	39
16	Rituximab in primary central nervous system lymphoma—A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2019, 37, 548-557.	0.8	54
17	Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies. <i>Journal of Clinical Epidemiology</i> , 2019, 114, 49-59.	2.4	20
18	GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. <i>Cell Reports</i> , 2019, 28, 3367-3380.e8.	2.9	37

#	ARTICLE	IF	CITATIONS
19	ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceded by clonally related lymphomatoid papulosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 763-767.	1.4	9
20	Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. <i>BMC Cancer</i> , 2019, 19, 287.	1.1	22
21	A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3026-3034.	3.2	29
22	3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck – a multicentre, retrospective analysis. <i>Radiation Oncology</i> , 2019, 14, 32.	1.2	30
23	Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. <i>ESMO Open</i> , 2019, 4, e000596.	2.0	4
24	CNS border posts against rituximab?. <i>Lancet Oncology, The</i> , 2019, 20, 169-170.	5.1	2
25	Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation. <i>PLoS ONE</i> , 2019, 14, e0210669.	1.1	10
26	Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 1-11.	2.4	77
27	Retrospective assessment of resource use and costs in two investigator-initiated randomized trials exemplified a comprehensive cost item list. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 73-83.	2.4	15
28	Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2018, 66, 346-354.	2.9	98
29	Web-Based Stress Management for Newly Diagnosed Patients With Cancer (STREAM): A Randomized, Wait-List Controlled Intervention Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 780-788.	0.8	71
30	The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. <i>Trials</i> , 2018, 19, 505.	0.7	17
31	Novel agents for primary central nervous system lymphoma: evidence and perspectives. <i>Blood</i> , 2018, 132, 681-688.	0.6	23
32	How to use FDA drug approval documents for evidence syntheses. <i>BMJ: British Medical Journal</i> , 2018, 362, k2815.	2.4	17
33	Ifosphamide and Carboplatin Based (R-DeVIC) Salvage Therapy in Patients with Relapsed/Refractory PCNSL - a Multicentre Retrospective Analysis. <i>Blood</i> , 2018, 132, 1705-1705.	0.6	0
34	High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. <i>Bone Marrow Transplantation</i> , 2017, 52, 1113-1119.	1.3	58
35	High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. <i>Leukemia</i> , 2017, 31, 2623-2629.	3.3	72
36	Premature Discontinuation of Pediatric Randomized Controlled Trials: A Retrospective Cohort Study. <i>Journal of Pediatrics</i> , 2017, 184, 209-214.e1.	0.9	23

#	ARTICLE	IF	CITATIONS
37	High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). <i>Leukemia</i> , 2017, 31, 846-852.	3.3	134
38	Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit. <i>Journal of Clinical Epidemiology</i> , 2017, 82, 12-19.	2.4	8
39	Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade. <i>BioMed Research International</i> , 2017, 2017, 1-5.	0.9	49
40	3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis. <i>Annals of Oncology</i> , 2017, 28, v382.	0.6	0
41	Agreements between Industry and Academia on Publication Rights: A Retrospective Study of Protocols and Publications of Randomized Clinical Trials. <i>PLoS Medicine</i> , 2016, 13, e1002046.	3.9	20
42	Premature Discontinuation of Prospective Clinical Studies Approved by a Research Ethics Committee – A Comparison of Randomised and Non-Randomised Studies. <i>PLoS ONE</i> , 2016, 11, e0165605.	1.1	22
43	Premature Discontinuation of Randomized Trials in Critical and Emergency Care. <i>Critical Care Medicine</i> , 2016, 44, 130-137.	0.4	28
44	Multivariable fractional polynomial interaction to investigate continuous effect modifiers in a meta-analysis on higher versus lower PEEP for patients with ARDS. <i>BMJ Open</i> , 2016, 6, e011148.	0.8	13
45	High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix). <i>BMC Cancer</i> , 2016, 16, 282.	1.1	53
46	The role of whole brain radiation in primary CNS lymphoma. <i>Blood</i> , 2016, 128, 32-36.	0.6	35
47	A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. <i>Journal of Clinical Epidemiology</i> , 2016, 80, 8-15.	2.4	130
48	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e388-e397.	2.2	128
49	The reporting of studies using routinely collected health data was often insufficient. <i>Journal of Clinical Epidemiology</i> , 2016, 79, 104-111.	2.4	51
50	Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition. <i>Annals of Oncology</i> , 2016, 27, vi24.	0.6	1
51	Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2016, 114, 256-261.	2.9	256
52	Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas. <i>Expert Review of Hematology</i> , 2016, 9, 123-135.	1.0	2
53	An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules. <i>Journal of Clinical Epidemiology</i> , 2016, 69, 152-160.	2.4	19
54	Early neutrophil to lymphocyte ratio dynamics to predict progression free survival in patients treated with immune-checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14513-e14513.	0.8	0

#	ARTICLE	IF	CITATIONS
55	High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group. <i>Blood</i> , 2016, 128, 781-781.	0.6	0
56	Quality of Life in Patients with Primary CNS Lymphoma - a Pooled Analysis from Three Prospective Multicentre Trials. <i>Blood</i> , 2016, 128, 5385-5385.	0.6	1
57	Completion and Publication Rates of Randomized Controlled Trials in Surgery. <i>Annals of Surgery</i> , 2015, 262, 68-73.	2.1	45
58	Immunotherapies in Early and Advanced Renal Cell Cancer. <i>Progress in Tumor Research</i> , 2015, 42, 1-10.	0.1	12
59	Prognostic score for patients with advanced melanoma treated with ipilimumab. <i>European Journal of Cancer</i> , 2015, 51, 2785-2791.	1.3	53
60	Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 999-1000.	1.3	20
61	First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)â€”a systematic review and individual patient data meta-analysis. <i>Annals of Oncology</i> , 2015, 26, 1305-1313.	0.6	152
62	Planning and reporting of quality-of-life outcomes in cancer trials. <i>Annals of Oncology</i> , 2015, 26, 1966-1973.	0.6	47
63	Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study. <i>BMC Cancer</i> , 2014, 14, 728.	1.1	42
64	Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. <i>BMJ, The</i> , 2014, 349, g4539-g4539.	3.0	74
65	Prevalence, Characteristics, and Publication of Discontinued Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1045.	3.8	265
66	The role of additional radiotherapy for primary central nervous system lymphoma. <i>The Cochrane Library</i> , 2014, , CD009211.	1.5	12
67	Investigation of continuous effect modifiers in a meta-analysis on higher versus lower PEEP in patients requiring mechanical ventilation - protocol of the ICEM study. <i>Systematic Reviews</i> , 2014, 3, 46.	2.5	5
68	Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. <i>BMJ, The</i> , 2014, 349, g4921-g4921.	3.0	5
69	High Dose-Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation for Patients with Refractory or Recurrent Primary Central Nervous System Lymphoma â€”Results of a Multicenter Study By the Germany Collaborative PCNSL Study Group. <i>Blood</i> , 2014, 124, 2527-2527.	0.6	0
70	Initiation and continuation of randomized trials after the publication of a trial stopped early for benefit asking the same study question: STOPIT-3 study design. <i>Trials</i> , 2013, 14, 335.	0.7	4
71	¹⁸ F-FDG PET Is an Independent Outcome Predictor in Primary Central Nervous System Lymphoma. <i>Journal of Nuclear Medicine</i> , 2013, 54, 184-191.	2.8	37
72	Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. <i>Haematologica</i> , 2013, 98, 765-770.	1.7	82

#	ARTICLE	IF	CITATIONS
73	Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study. <i>Annals of Oncology</i> , 2012, 23, 2670-2675.	0.6	93
74	Fibrates for primary prevention of cardiovascular disease events. , 2012, , .		8
75	Learning from failure - rationale and design for a study about discontinuation of randomized trials (DISCO study). <i>BMC Medical Research Methodology</i> , 2012, 12, 131.	1.4	33
76	The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. <i>Annals of Hematology</i> , 2012, 91, 1257-1264.	0.8	13
77	Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg. <i>Blood</i> , 2012, 120, 302-302.	0.6	17
78	First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) — A Systematic Review and Individual Patient Data Meta-Analysis. <i>Blood</i> , 2012, 120, 3655-3655.	0.6	1
79	Meta-analyses: what they can and cannot do. <i>Swiss Medical Weekly</i> , 2012, 142, w13518.	0.8	57
80	Management of Multiple Myeloma in Pregnancy: Strategies for a Rare Challenge. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 190-197.	0.2	21
81	Primary CNS Lymphoma—Radiation-Free Salvage Therapy by Second Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 281-283.	2.0	16
82	Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. <i>Annals of Oncology</i> , 2011, 22, 2080-2085.	0.6	107
83	Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation - a Multicenter Retrospective Analysis. <i>Blood</i> , 2011, 118, 3089-3089.	0.6	1
84	FDG-PET Is An Independent Predictor for Survival in Primary Central Nervous System Lymphoma. <i>Blood</i> , 2011, 118, 2687-2687.	0.6	0
85	Para-aortic lymph node metastasis in malignant dysgerminoma of the ovary. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2009, 88, 1288-1290.	1.3	15
86	Stem Cell Migration in Health and Disease. <i>Translational Research in Biomedicine</i> , 2009, , 7-27.	0.4	0
87	Modulation of Hematopoietic Stem/Progenitor Cell Migration. , 2009, , 57-77.		0
88	The stromal cell-derived factor-1 α dependent migration of human cord blood CD34 ⁺ haematopoietic stem and progenitor cells switches from protein kinase C (PKC) α dependence to PKC β independence upon prolonged culture in the presence of Flt3 ligand and interleukin-6. <i>British Journal of Haematology</i> , 2008, 142, 831-835.	1.2	11
89	Stem Cell Migration: A Quintessential Stepping Stone to Successful Therapy. <i>Current Stem Cell Research and Therapy</i> , 2007, 2, 89-103.	0.6	47